Are you Dr. Ko?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 4 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
330 Brookline Ave
Beth Israel Deaconess Med
Boston, MA 02215
Summary
- Dr. Yoo-Joung Ko, MD is an oncologist in Boston, Massachusetts.
Education & Training
Beth Israel Deaconess Medical CenterFellowship, Hematology and Medical Oncology, 1996 - 1999
Clinical Trials
- Single Agent Abraxane as Second Line Therapy in Bladder Cancer Start of enrollment: 2008 Mar 01
- SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC) Start of enrollment: 2012 Dec 01
- Study of TRIFLURIDINE/TIPIRACIL in Previously Treated Cholangiocarcinoma Start of enrollment: 2019 Dec 11
Publications & Presentations
PubMed
- 19 citationsSafety and feasibility of initiating a hepatic artery infusion pump chemotherapy program for unresectable colorectal liver metastases: A multicenter, retrospective coh...Hala Muaddi, Michael I. D’Angelica, Jason T. Wiseman, Mary Dillhoff, Nicholas Latchana
Journal of Surgical Oncology. 2021-01-01 - 14 citationsAflibercept Plus FOLFIRI for Second-line Treatment of Metastatic Colorectal Cancer: Observations from the Global Aflibercept Safety and Health-Related Quality-of-Life ...Rachel P. Riechelmann, Vichien Srimuninnimit, Roberto Bordonaro, Petr Kavan, Maria Di Bartolomeo
Clinical Colorectal Cancer. 2019-09-01 - 2 citationsComplete response as an intermediate end point in patients receiving salvage systemic therapy for urothelial carcinoma.Guru Sonpavde, Gregory R. Pond, Jonathan E. Rosenberg, Dean F. Bajorin, Ashley Marie Regazzi
Clinical Genitourinary Cancer. 2015-04-01
Professional Memberships
- Member
